SM
AST

Sabby Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Sabby Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$92K – 368
2016
Q4 		$92K Hold
200
– – 0.01% 269
2016
Q3 		$85K Buy
+200
New +$647 ﹤0.01% 293

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sabby Management's AST Position: Q3 2016 in Review

Sabby Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2016, closing a stake of 308,909 shares — an estimated $999K sold.

Sabby Management first reported a position in AST in Q2 2016 and held it in 1 quarter. The position peaked at $741K in Q2 2016. 64 funds tracked by Wall St. Rank hold AST as of Q3 2016.

  • Sabby Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 308,909 Asterias Biotherapeutics Inc. Series A shares in Q3 2016, an estimated $999K.
  • Sabby Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 1 quarter.
  • Sabby Management's Asterias Biotherapeutics Inc. Series A position peaked at $741K in Q2 2016.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.